secwatch.observer — SEC 8-K summary
======================================

Issuer:     Insight Molecular Diagnostics Inc. (IMDX)
CIK:        0001642380
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001493152-23-006511
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncocyte appoints Joshua Riggs as permanent CEO, President, and Board member
----------------------------------------------------------------------------

- Joshua Riggs appointed CEO effective Feb 24, 2023; also named President and joined Board on Feb 28.
- Riggs served as interim CEO since Dec 2022, leading restructuring and cost reduction initiatives.
- Board unanimously supports Riggs' appointment; Chair Andy Arno cites rapid spend reduction and strategic refocus.
- Riggs previously held roles as General Manager, Transplant and Senior Director of Business Development at Oncocyte.
- Company continues focus on precision diagnostics: DetermaIO, VitaGraft, and pipeline test DetermaCNI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223006511/0001493152-23-006511-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642380/000149315223006511/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-006511

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer